natgillin/translations-raw huggingface dataset:
The pharmacokinetics of robenacoxib injection do not differ between male and female cats and dogs, and are linear over the range of 0.25–4 mg/kg in dogs.
Nema razlike između farmakokinetike robenakoksiba između ženki i mužjaka pasa i mačaka te su u oba slučaja linearne u rasponu od 0,25 - 4 mg/kg u pasa.
The pharmacokinetics of sacubitril, LBQ657 and valsartan were approximately linear over an Neparvis dose range of 24 mg sacubitril/26 mg valsartan to 97 mg sacubitril/103 mg valsartan.
Farmakokinetika sakubitrila, LBQ657 i valsartana bila je otprilike linearna u rasponu doza Neparvisa od 24 mg sakubitrila/26 mg valsartana do 97 mg sakubitrila/103 mg valsartana.
The pharmacokinetics of selexipag and the active metabolite in PAH patients were not influenced by the severity of the disease and did not change with time.
Farmakokinetika seleksipaga i aktivnog metabolita u bolesnika s PAH- om nije bila pod utjecajem težine bolesti i nije se mijenjala s vremenom.
The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.
Nije ispitivana farmakokinetika sildenafila u bolesnika s teškim oštećenjem jetre.
The pharmacokinetics of sirolimus were similar in various populations, with renal function ranging from normal to absent (dialysis patients).
Farmakokinetika sirolimusa bila je slična u različitim populacijama s funkcijom bubrega u rasponu od normalne do odsutne (bolesnika na dijalizi).
The pharmacokinetics of SIRTURO in paediatric patients have not been evaluated.
Farmakokinetika lijeka SIRTURO nije procijenjena u pedijatrijskih bolesnika.
The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2 diabetes.
Farmakokinetika sitagliptina u načelu je bila slična u zdravih osoba i u bolesnika s dijabetesom tipa 2.
The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2 diabetes.
Farmakokinetika sitagliptina u načelu je slična u zdravih ispitanika i bolesnika s dijabetesom tipa 2.
The pharmacokinetics of sodium oxybate in paediatric patients under the age of 18 years have not been studied.
Farmakokinetika natrijeva oksibata nije ispitivana u pedijatrijskih bolesnika mlađih od 18 godina.
The pharmacokinetics of sofosbuvir was studied in HCV negative patients with mild (eGFR ≥ 50 and
Farmakokinetika sofosbuvira bila je ispitana u HCV-negativnih pacijenata s blagim (eGFR ≥ 50 i
The pharmacokinetics of sofosbuvir were studied in HCV negative patients with mild (eGFR ≥ 50 and
Farmakokinetika sofosbuvira bila je ispitana u HCV-negativnih pacijenata s blagim (eGFR ≥ 50 i
The pharmacokinetics of sofosbuvir were studied in HCV negative subjects with mild (eGFR ≥50 and
Farmakokinetika sofosbuvira bila je ispitana u HCV-negativnih ispitanika s blagim (eGFR ≥ 50 i
The pharmacokinetics of Soliris have been studied in aHUS patients with a range of renal impairment and age.
Farmakokinetika lijeka Soliris ispitivala se u bolesnika s aHUS-om koji su imali širok raspon oštećenja funkcije bubrega te u bolesnika različitih dobnih skupina.
The pharmacokinetics of sonidegib were examined in subjects with mild (Child-Pugh class A; n=8), moderate (Child-Pugh class B; n=8) or severe (Child-Pugh class C; n=9) hepatic impairment and in 8 healthy subjects with normal hepatic function.
Farmakokinetika sonidegiba ispitivana je u ispitanika s blagim (Child-Pugh stadij A; n=8), umjerenim (Child-Pugh stadij B; n=8) ili teškim (Child-Pugh stadij C; n=9) oštećenjem jetre te u 8 zdravih ispitanika s normalnom jetrenom funkcijom.
The pharmacokinetics of stavudine was independent of time, since the ratio between AUC(ss) at steady state and the AUC(0-t) after the first dose was approximately 1.
Farmakokinetika stavudina nije ovisila o vremenu, budući da je omjer AUC(ss) pri stanju dinamičke ravnoteže i AUC(0-t) nakon prve doze bio otprilike 1.
The pharmacokinetics of strontium and ranelic acid have been assessed in healthy young men and healthy postmenopausal women, as well as during long- term exposure in men with osteoporosis and postmenopausal osteoporotic women including elderly women.
Farmakokinetika stroncija i ranelatne kiseline bile su procijenjene u zdravih mladih muškaraca i u zdravih žena u poslijemenopauzi, kao i pri dugotrajnoj izloženosti u muškaraca s osteoporozom i u žena u poslijemenopauzi s osteoporozom, uključivši starije žene.
The pharmacokinetics of sufentanil after sublingual administration can be described as a three- compartment model with first-order absorption.
Farmakokinetika sufentanila nakon sublingvalne primjene može se opisati kao model s tri odjeljka i apsorpcijom prvog reda.
The pharmacokinetics of sunitinib were evaluated in 135 healthy volunteers and 266 patients with solid tumours.
Farmakokinetika sunitiniba bila je ispitana u 135 zdravih dobrovoljaca te u 266 bolesnika sa solidnim tumorima.
The pharmacokinetics of tacrolimus after topical application are similar to those reported in adults, with minimal systemic exposure and no evidence of accumulation (see above).
Farmakokinetika takrolimusa nakon topikalne primjene slična onoj zabilježenoj u odraslih, uz minimalnu sistemsku izloženost i bez dokazanog nakupljanja (vidjeti gore).
The pharmacokinetics of technetium Tc 99m tilmanocept in patients with renal or hepatic impairment have not been characterised (see section 5.2).
Farmakokinetika tilmanocepta obilježenog radioaktivnim tehnecijem Tc 99m u bolesnika s oštećenom funkcijom bubrega ili jetre nije opisana (vidjeti dio 5.2.).
The pharmacokinetics of tedizolid in elderly healthy volunteers (age 65 years and older, with at least 5 subjects at least 75 years old; n=14) was comparable to younger control subjects (25 to 45 years old; n=14) following administration of a single oral dose of Sivextro 200 mg.
Farmakokinetika tedizolida u starijih zdravih dobrovoljaca (u dobi od 65 ili više godina, s najmanje 5 ispitanika u dobi od najmanje 75 godina; n=14) bila je usporediva s mlađim kontrolnim ispitanicima (u dobi od 25 do 45 godina; n=14) nakon primjene jednokratne peroralne doze lijeka Sivextro od 200 mg.
The pharmacokinetics of tedizolid were evaluated in adolescent subjects (12 to 17 years; n=20) following administration of a single oral or IV dose of Sivextro 200 mg.
Farmakokinetika tedizolida procijenjena je u ispitanika u adolescentnoj dobi (od 12 do 17 godina; n=20) nakon primjene jednokratne peroralne ili intravenske doze lijeka Sivextro od 200 mg.
The pharmacokinetics of telavancin in patients below 18 years of age have not been established (see section 4.2).
Farmakokinetika telavancina kod bolesnika mlađih od 18 godina još nije ustanovljena (vidjeti dio 4.2).
The pharmacokinetics of telithromycin is similar between males and females.
Farmakokinetika telitromicina podjednaka je u muškaraca i žena.
The pharmacokinetics of tenofovir has been studied in patients with hepatic impairment and no dose adjustment is required.
Farmakokinetika tenofovira ispitana je u bolesnika s oštećenjem jetrene funkcije i nije potrebno prilagođavati dozu.
The pharmacokinetics of tenofovir have been studied in patients with hepatic impairment and no dose adjustment is required in these patients.
Farmakokinetika tenofovira ispitana je u pacijenata s oštećenjem jetre i u tih pacijenata nije potrebna prilagodba doze.
The pharmacokinetics of tenofovir have not been specifically studied in different ethnic groups.
Farmakokinetika tenofovira nije posebno ispitivana u skupinama različite etničke pripadnosti.
The pharmacokinetics of tenofovir in paediatric patients with renal impairment have not been studied.
Farmakokinetika tenofovira u pedijatrijskih pacijenata s oštećenjem funkcije bubrega nije ispitana.
The pharmacokinetics of tenofovir were independent of tenofovir disoproxil fumarate dose over the dose range 75 to 600 mg and were not affected by repeated dosing at any dose level.
Farmakokinetika tenofovira je nezavisna od doze tenofovirdizoproksilfumarata u rasponu doza od 75 do 600 mg i nije pod utjecajem ponovljenih doza bilo koje jačine.
The pharmacokinetics of the metabolites is derived from a single study with five patients.
Farmakokinetika metabolita je izvedena iz jednog ispitivanja na pet pacijenata.
The pharmacokinetics of theophylline, a CYP1A2 substrate, were not significantly affected by co- administration with duloxetine (60 mg twice daily).
Nije bilo znatnijeg utjecaja na farmakokinetiku teofilina, koji je supstrat CYP1A2, prilikom istodobne primjene s duloksetinom (60 mg dva puta dnevno).
The pharmacokinetics of tocilizumab was determined using a population pharmacokinetic analysis on a database composed of 188 patients with pJIA.
Farmakokinetika tocilizumaba odredila se populacijskom farmakokinetičkom analizom iz baze podataka koja se sastojala od 188 bolesnika oboljelih od pJIA.
The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with 162 mg subcutaneous every week, 162 mg subcutaneous every other week, and or 4 or 8 mg/kg intravenous every 4 weeks for 24 weeks.
Farmakokinetika tocilizumaba odredila se populacijskom farmakokinetičkom analizom iz baze podataka sastavljene od 3552 bolesnika s RA liječenih supkutanom dozom od 162 mg jedanput tjedno, supkutanom dozom od 162 mg jedanput svaka dva tjedna ili intravenskom dozom od ili 4 ili 8 mg/kg jedanput svaka 4 tjedna tijekom razdoblja od 24 tjedna.
The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 75 sJIA patients treated with 8 mg/kg (patients with a body weight ≥ 30 kg ) or 12 mg/kg (patients with a body weight < 30 kg), given every 2 weeks.
Farmakokinetika tocilizumaba odredila se populacijskom farmakokinetičkom analizom iz baze podataka koja se sastojala od 75 bolesnika oboljelih od sJIA koji su primali 8 mg/kg (bolesnici tjelesne težine ≥ 30 kg) ili 12 mg/kg (bolesnici tjelesne težine < 30 kg) svaka dva tjedna.
The pharmacokinetics of topotecan given as a 30 minute infusion for 5 days were evaluated in two studies.
Farmakokinetika topotekana primijenjenog u obliku 30-minutne infuzije tijekom 5 dana procjenjivana je u dva ispitivanja.
The pharmacokinetics of topotecan was generally unchanged when coadministered with ranitidine.
Farmakokinetika topotekana općenito je nepromijenjena pri istovremenoj primjeni s ranitidinom.
The pharmacokinetics of total cobalamins-(III) in this population may be affected by the body's cyanide load, since cyanocobalamin was reported to exhibit a 2-3 times lower half-life than total cobalamins-(III) in healthy volunteers.
Na farmakokinetiku ukupnog kobalamina-(III) u ovoj populaciji može utjecati opterećenje cijanidom u tijelu, jer je prijavljeno da cijanokobalamin pokazuje 2–3 puta kraći poluvijek od ukupnih kobalamina-(III) kod zdravih dobrovoljaca.
The pharmacokinetics of Truvada have not been studied in subjects with hepatic impairment.
Farmakokinetika Truvade nije ispitana u ispitanika s oštećenjem funkcije jetre.
The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis or Crohn’s disease.
Istodobna primjena MXT, NSAIL, 6-merkaptopurina, azatioprina i oralnih kortikosteroida, ili prethodna izloženost anti-TNFα lijekovima, nije imala utjecaj na farmakokinetiku ustekinumaba kod bolesnika s psorijatičnim artritisom ili Crohnovom bolesti.
The pharmacokinetics of ustekinumab were generally comparable between Asian and non-Asian patients with psoriasis.
Farmakokinetika ustekinumaba bila je općenito usporediva kod bolesnika s psorijazom azijskog i ne- azijskog porijekla.
The pharmacokinetics of vandetanib at the 300 mg dose in MTC patients are characterised by a clearance of approximately 13.2 l/h. and plasma half-life of approximately 19 days.
Farmakokinetiku vandetaniba pri dozi od 300 mg u bolesnika s medularnim karcinomom štitnjače obilježava klirens od oko 13,2 l/h i vrijeme polueliminacije u plazmi od približno 19 dana.
The pharmacokinetics of vardenafil in patients with severely impaired hepatic function (Child-Pugh C) has not been studied (see section 4.3).
Farmakokinetika vardenafila u bolesnika s teško oštećenom jetrenom funkcijom (Child-Pugh C) nije ispitana (vidjeti dio 4.3).
The pharmacokinetics of varenicline in elderly patients with normal renal function (aged 65-75 years) is similar to that of younger adult subjects (see section 4.2).
Farmakokinetika vareniklina u starijih bolesnika s normalnom bubrežnom funkcijom (u dobi 65-75 godina) slična je onoj u mlađih odraslih ispitanika (vidjeti dio 4.2).
The pharmacokinetics of velpatasvir was studied with a single dose of 100 mg velpatasvir in HCV negative patients with moderate and severe hepatic impairment (CPT Class B and C).
Farmakokinetika velpatasvira bila je ispitana nakon jedne doze od 100 mg velpatasvira u HCV- negativnih bolesnika s umjerenim i teškim oštećenjem jetre (CPT stadij B i C).
The pharmacokinetics of verteporfin have been reported to be similar in healthy Caucasian and Japanese men after a dose of 6 mg/m2 by a 10-minute infusion.
Farmakokinetika verteporfina je prema izvješćima bila slična u zdravih bijelaca i Japanaca nakon primjene doze od 6 mg/m2 intravenskom infuzijom u trajanju od 10 minuta.
The pharmacokinetics of Vipdomet in children and adolescents < 18 years old has not been established.
Farmakokinetika Vipdometa u djece i adolescenata < 18 godina starosti nije utvrđena.
The pharmacokinetics of Voncento have been evaluated in haemophilia A patients in the non-bleeding state.
Farmakokinetika Voncenta procijenjena je u bolesnika s hemofilijom A u stanju bez krvarenja.
The pharmacokinetics of Voncento have been evaluated in VWD patients in the non-bleeding state.
Farmakokinetika Voncenta procijenjena je u bolesnika s von Willebrandovom bolešću u stanju bez krvarenja.
The pharmacokinetics of zonisamide in patients with impaired liver function have not been adequately studied.
Farmakokinetika zonisamida u bolesnika s oštećenom funkcijom jetre nije bila odgovarajuće ispitana.
The pharmacokinetics were similar in all solid tumours populations tested and in healthy volunteers.
Farmakokinetika je bila podjednaka u svim solidnim tumorima i u zdravih dobrovoljaca.
The pharmacokinetics, efficacy and safety of Envarsus and tacrolimus immediate-release capsules , both in combination with corticosteroids was compared in 117 liver transplant recipients, of whom 88 received treatment with Envarsus.
Farmakokinetika, djelotvornost i sigurnost Envarsusa i kapsula takrolimusa s trenutnim oslobađanjem, oba u kombinaciji s kortikosteroidima, uspoređena je u 117 primatelja presatka jetre od kojih je 88 liječeno Envarsusom.
The pharmacokinetics, safety and efficacy of Atripla have not been established in patients with significant underlying liver disorders (see section 5.2).
Nisu ustanovljene farmakokinetika, sigurnost i djelotvornost Atriple u pacijenata sa značajnim postojećim oštećenjima funkcije jetre (vidjeti dio 5.2).
The pharmacokinetics, safety, tolerability and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, was evaluated in trial TMC278-C213, a single-arm, open-label Phase 2 trial in antiretroviral treatment-naïve HIV-1 infected adolescent subjects weighing at least 32 kg.
Farmakokinetika, sigurnost, podnošljivost i djelotvornost rilpivirina u dozi od 25 mg jedanput dnevno, u kombinaciji s osnovnim režimom po izboru ispitivača koji je sadržavao dva NRTI, bili su procijenjeni u ispitivanju TMC278-C213, otvorenom ispitivanju faze 2 s jednom skupinom ispitanika, u adolescenata zaraženih virusom HIV-1 koji prethodno nisu bili liječeni antiretrovirusnom terapijom, tjelesne težine od najmanje 32 kg.
The pharmacologic effects of beta2-adrenergic agonists, including vilanterol, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’,5’-adenosine monophosphate (cyclic AMP).
Farmakološki učinci agonista beta2-adrenergičkih agonista, uključujući vilanterol, barem se djelomično mogu pripisati stimulaciji unutarstanične adenilat ciklaze, enzima koji katalizira pretvorbu adenozin trifosfata (ATP) u ciklički-3',5'-adenozin monofosfat (ciklički AMP).
The pharmacologic effects of beta2-adrenoceptor agonist drugs, including vilanterol trifenatate, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’,5’-adenosine monophosphate (cyclic AMP).
Farmakološki učinci agonista beta2-adrenoreceptora, uključujući vilanteroltrifenatat, barem se djelomično mogu pripisati stimulaciji unutarstanične adenilat ciklaze, enzima koji katalizira pretvorbu adenozin trifosfata (ATP) u 3',5'-ciklički adenozin monofosfat (ciklički AMP).
The pharmacological effects of beta2-adrenoceptor agonists are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate).
Farmakološki učinci beta2-adrenoceptorskih agonista mogu se barem djelomično pripisati stimulaciji unutarstanične adenil ciklaze, enzima koji katalizira konverziju adenozin trifosfata (ATP) u ciklički- 3’, 5’-adenozin monofosfat (ciklički monofosfat).
The pharmacological effects of beta2-adrenoceptor agonists, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic AMP).
Farmakološki učinci beta2-adrenoceptorskih agonista, što uključuje indakaterol, mogu se barem djelomično pripisati stimulaciji unutarstanične adenil ciklaze, enzima koji katalizira konverziju adenozin trifosfata (ATP) u ciklički-3’, 5’-adenozin monofosfat (ciklički AMP).
The pharmacological effects of β2 agonist treatment, such as tremor, palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy.
Zabilježeni su farmakološki učinci liječenja β2-agonistima, kao što su tremor, palpitacije i glavobolja, ali obično su prolazni i smanjuju se s redovitom terapijom.
The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy-mycolic and keto-mycolic acid.
Farmakološki način djelovanja delamanida uključuje inhibiciju sinteze komponenti stanične stijenke mikobakterija, metoksi-mikolne i keto-mikolne kiseline.
The pharmacological properties of Plegridy are consistent with those of interferon beta-1a and are believed to be mediated by the protein portion of the molecule.
Farmakološka svojstva Plegridyja su u skladu s onima od interferona beta-1a i vjeruje se da su posredovana proteinskim dijelom molekule.
The pharmacological response elicited by alpha-2 agonists (e.g. dexmedetomidine) in such animals may be reduced.
Farmakološka reakcija potaknuta alfa-2 antagonistima (na primjer, deksmedetomidin) u takvih životinja može biti slabija.
The pharmacy preparation should be preferred to home preparation.
Za dojenčad mlađu od 1 godine prednost treba dati ljekarničkom pripravku u odnosu na pripravak izrađen kod kuće.
The Phase 1 and 2 studies assessed the safety of idelalisib in a total of 535 subjects with haematologic malignancies, including 399 subjects who received idelalisib (any dose) as a single agent and 136 subjects who received idelalisib in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab).
Ispitivanja faze 1 i 2 procjenjivala su sigurnost primjene idelalisiba u ukupno 535 ispitanika s hematološkim zloćudnim bolestima, uključujući 399 ispitanika koji su primali idelalisib (bilo koju dozu) kao monoterapiju i 136 ispitanika koji su primali idelalisib u kombinaciji s anti-CD20 monoklonskim protutijelom (rituksimabom ili ofatumumabom).
The Phase 1 pharmacokinetics showed proportionality within the dose interval (0.5 – 8 mg) as reflected in Cmax values.
Farmakokinetička ispitivanja faze I pokazala su proporcionalnost unutar intervala doziranja (0,5-8 mg) što se odražavalo i u vrijednostima Cmax.
The phase 3 pivotal trial (TEMPO 3:4, 156-04-251) included subjects from 129 centres in the Americas, Japan, Europe and other countries.
Pivotalno ispitivanje faze 3 (TEMPO 3:4, 156-04-251) uključilo je ispitanike iz 129 centara na Američkom kontinentu, u Japanu, Europi i drugim zemljama.
The phase 3 studies conducted with ZYTIGA excluded patients with uncontrolled hypertension, clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association Class (NYHA) III or IV heart failure (study 301) or Class II to IV heart failure (study 302) or cardiac ejection fraction measurement of < 50%.
U ispitivanjima faze III provedenim s lijekom ZYTIGA nisu uključivani bolesnici s nekontroliranom hipertenzijom, klinički značajnom bolešću srca koja se manifestirala infarktom miokarda ili arterijskim trombotičkim događajima u prethodnih 6 mjeseci, bolesnici s teškom ili nestabilnom anginom te bolesnici sa zatajivanjem srca stupnja III i IV (ispitivanje 301) ili sa zatajivanjem srca stupnja II do IV (ispitivanje 302), prema New York Heart Association (NYHA) ili ejekcijskom frakcijom srca < 50%.
The Phase 3 studies were all conducted with peginterferon alfa-2a in combination with INCIVO and ribavirin.
Faze III svih ispitivanja provedena su s peginterferonom alfa-2a u kombinaciji s INCIVOM i ribavirinom.
The Phase 3 trials of lumacaftor/ivacaftor included 81 patients with ppFEV1 <40 at baseline.
U ispitivanja lumakaftora/ivakaftora faze 3 bio je uključen 81 bolesnik s ppFEV1 < 40 na početku ispitivanja.
The phase II trial (study 001/007) enrolled only women who:
U ispitivanje faze II (ispitivanje 001/007) uključene su samo žene koje su:
The Phase III clinical development programme included approximately 4,000 patients with a clinical diagnosis of COPD and comprised two 6-month randomised, placebo- and active-controlled studies (ACLIFORM-COPD and AUGMENT), a 6-month extension of the AUGMENT study and a further 12- month randomised controlled study.
Program kliničkog razvoja faze III uključivao je otprilike 4000 bolesnika s kliničkom dijagnozom KOPB-a i sastojao se od dva 6-mjesečna randomizirana, placebom i aktivnim lijekom kontrolirana ispitivanja (ACLIFORM-COPD i AUGMENT), 6-mjesečni produžetak ispitivanja AUGMENT i daljnje 12-mjesečno randomizirano, kontrolirano ispitivanje.
The Phase III clinical development programme included approximately 4,000 patients with a clinical diagnosis of COPD and comprised two 6-month randomised, placebo- and active-controlled studies (ACLIFORM-COPD and AUGMENT), a 6-month extension of the AUGMENT study and a further 12-month randomised controlled study.
Program kliničkog razvoja faze III uključivao je otprilike 4000 bolesnika s kliničkom dijagnozom KOPB-a i sastojao se od dva 6-mjesečna randomizirana, placebom i aktivnim lijekom kontrolirana ispitivanja (ACLIFORM-COPD i AUGMENT), 6-mjesečni produžetak ispitivanja AUGMENT i daljnje 12-mjesečno randomizirano, kontrolirano ispitivanje.
The Phase III studies were blindly evaluated, prospective, intra-individually controlled, randomised, multicentre trials.
Ispitivanja faze III bila su , prospektivna, intraindividualno kontrolirana, randomizirana, multicentrična ispitivanja procjenjivana na slijepo .
The phase III trial (study 008) enrolled women without pre-screening for the presence of HPV infection, i.e. regardless of baseline cytology and HPV serological and DNA status.
U ispitivanje faze III (ispitivanje 008) uključene su žene bez prethodnog probira na prisutnost HPV infekcije, odnosno uključene su bez obzira na početni citološki nalaz i bez obzira na HPV serološki i DNA status.
The Philadelphia-chromosome is found in some ALL patients and is present in most patients with CML.
Philadelphia kromosom nalazi se kod nekih bolesnika s ALL-om te je prisutan u većine bolesnika s KML-om.